Thromboelastography-guided recombinant factor VIIa administration in a patient with refractory autoimmune idiopathic thrombocytopenia

Anesthesia and Analgesia

Volumn 107, Issue 2, 2008, Pages 402-405

  James, Katherine M H ^a   Melikian, Clare N ^a   Chowdary, Pratima ^a   Mallett, Susan V ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DANAZOL; HEMOGLOBIN; IMMUNOGLOBULIN; LUPUS ANTICOAGULANT; RECEPTOR ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADJUVANT THERAPY; ADULT; ANTIBODY TITER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLADDER IRRIGATION; BLEEDING; CANCER CHEMOTHERAPY; CASE REPORT; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; EPISTAXIS; ERYTHROCYTE TRANSFUSION; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HODGKIN DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PERIOPERATIVE PERIOD; POINT OF CARE TESTING; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; TREATMENT FAILURE; BLOOD; HOSPITAL INFORMATION SYSTEM;

ADULT; FACTOR VIIA; HEMORRHAGE; HEMOSTATICS; HUMANS; MALE; PERIOPERATIVE CARE; PLATELET COUNT; POINT-OF-CARE SYSTEMS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECOMBINANT PROTEINS; SPLENECTOMY; THROMBELASTOGRAPHY;

EID: 49949112567     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181770b87     Document Type: Article

References (18)

1. Chong BH. Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. Crit Rev Oncol Hematol 1995; 20:271-96
2. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106:2244-51
3. Wang ZY, Shen ZX. Megakaryocytes and platelets in immune thrombocytopenic purpura. Baillieres Clin Haematol 1997; 10:89-107
4. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623-34
5. Wrobel G, Dobaczewski G, Patkowski D, Sokol A, Grotthus E. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatric Blood Cancer 2002;47:729-30
6. Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Cristakis J. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol 2002;69:219-22
7. Gerotziafas GT, Chakroun T, Depasse F, Arzoglou P, Samama MM, Elalamy I. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 2004;91:977-85
8. Segal HC, Briggs C, Kunka S, Casbard A, Harrison P, Machin SJ, Murphy MF. Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. Br J Haematol 2005;128:520-5
9. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983;71:1836-41
10. Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000;83:634-5
11. Busani S, Marietta M, Pasetto A, Girardis M. Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage. Thromb Haemost 2005;93:381-2
12. Coppola A, Simone CD, Palmieri NM, Coppola D, Lanza F, Ruosi C, Amoriello A, Di Minno G. Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome. Blood Coagul Fibrinolysis 2007;18:199-201
13. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004;2:102-10
14. Hendricks H. Effects of recombinant activated VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 2002;13:309-13
15. Dargaud Y, Bordet JC, Trzeciak MC, Vinciguerra C, Negrier C. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica 2006;91:ECR20
16. Kawaguchi C, Takahashi Y, Hanesaka Y, Yoshioka A. The in vitro analysis of the coagulation mechanism of activated factor VII using thrombelastogram. Thromb Haemost 2002;88:768-72
17. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001;114:114-20
18. Savani BN, Dunbar CE, Rick ME. Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. Am J Hematol 2006;81:218-19